RDHL News and Press, Redhill Biopharma Ltd. From 11/07/22

RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates PR Newswire Financial update : Q2/22: Net revenues of $18.3 million ; Operating loss of $9.2 million ; Cash balance [1] of $43.2 million as of June 30, 2022 ; Restated Q1/22...

RedHill Presents New Talicia® Data Analyses at Obesity Week 2022 PR Newswire Talicia's efficacy, in this analysis of pooled data from two Phase 3 studies, was unaffected by presence of diabetes or elevated body mass index (BMI); additionally, pharmacokin...

RedHill Presents New Talicia® and Movantik® Data Analyses at ACG 2022 PR Newswire Physiologically-Based Pharmacokinetic (PBPK) modeling study of Talicia evaluated intragastric antibiotic exposure, critical for successful H. pylori eradication, comparing l...

Are You Using These Penny Stocks Trading Techniques? One of the most effective ways to make money with penny stocks is by using a trading strategy. There are many different strategies that you can use in your penny stock trading , and each has its own advantages and disadvantages. ...

%Healthcare stocks have absolutely been dominating the headlines space. Earlier today we wrote about a biotech stock, and now we’re switching to a drug manufacturing company. %RedhillBiopharma ($RDHL) turned heads during Wednesday’s session after the company announ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Redhill Biopharma (NASDAQ: RDHL ) stock is rocketing higher on Wednesday after the company received a patent for one of its oral antiviral treatments. That patent covers the administrati...

RedHill Biopharma ( NASDAQ: RDHL ) on Wednesday said that the U.S. Patent and Trademark Office (USPTO) granted a new method of use patent which protects the administration of its oral antiviral drug opaganib for certain patients with COVID-19. The new method of us...

RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent PR Newswire USPTO grants new method of use patent for the inhibition of a disease caused by a coronavirus in patients having pneumonia and receiving supplemental oxygen at a frac...

RedHill Biopharma ( NASDAQ: RDHL ) received Nasdaq non compliance notification on October 12, 2022 regarding minimum bid price deficiency. The bid price for the company's ADSs had closed below the minimum $1.00/share for the last thirty consecutive business...

RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency PR Newswire TEL AVIV, Israel & RALEIGH, N.C. , Oct. 18, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a sp...